DETECTING EGFR MUTATIONS IN PATIENTS
WITH NON-SMALL CELL LUNG CANCER Hammoudeh ZA, Antonova O, Staneva R, Nikolova D, Kyuchukov Y,
Penev A, Mintchev T, Koleva V, Hadjidekova S, Toncheva D *Corresponding Author: Zora A. Hammoudeh, Molecular Biologist, Department of Medical Genetics, Medical University Sofia,
2 Zdrave Str., 1431 Sofia, Bulgaria. Tel: +359-2-917-2735. Mobile: +359-88-943-0505. E-mail: zorahammoudeh@yahoo.com page: 13 download article in pdf format
|
Abstract
Mutations in the receptor of the epidermal growth
factor receptor (EGFR) in non-small cell lung cancer
(NSCLC) are used as biomarkers for predicting the response
of treatment with EGFR tyrosine kinase inhibitors
(EGFR TKIs). Non-small cell lung cancer patients usually
have activating EGFR mutations that leads to a very good
response when they are treated with EGFR TKIs. Our tumor
samples were examined for the presence of sensitive
mutations in the EGFR gene, resistant mutations or the
absence of mutations. To identify the types of the mutation,
we used a real-time polymerase chain reaction (RT-PCR)
method. Additionally, we evaluated the frequency of EGFR
mutations and their association with smoking status, gender
and histology. The tumor samples (n = 551) were tested
for 29 somatic mutations in the EGFR gene. Sensitive
mutations in the EGFR genes were found in 55 NSCLC
samples (10.0%). The prevalence of EGFR mutations was
much higher for females than for males (27.1 vs. 3.9%, p
<0.001). The prevalence of EGFR mutations was greater
in subjects who had never smoked than in smokers (15.0
vs. 6.08%, p <0.003). Additionally, the frequency of EGFR
mutations was higher in adenocarcinomas than in other
histological types (14.9 vs. 5.1%; p <0.001). Our results
show that activating mutations on the EGFR gene are more
frequent in females than in males, in adenocarcinoma than
other histological types and in non smokers than smokers.
|
|
|
|
|
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|